MERCK U.S. PATENT RIGHTS
FOR PRODUCTS

In accordance with Section 287(a) of Title 35 of the United States Code, the following list identifies Merck’s rights in U.S. patents associated with the relevant product. This list may be a subset of Merck’s rights in U.S. patents directed to the relevant product.



A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | X | Y | Z



Activyl®
(indoxacarb)
U.S. Patent No. 8,475,818
BRAVECTO™
(fluralaner)
U.S. Patent No. 7,662,972
U.S. Patent No. 8,796,464
U.S. Patent No. 8,022,089
U.S. Patent No. 8,492,311
U.S. Patent No. 9,173,870
Mometamax®
GENTAMICIN SULFATE, USP; MOMETASONE FUROATE MONOHYDRATE; AND CLOTRIMAZOLE, USP, OTIC SUSPENSION
U.S. Patent No. 6,127,353
Nobivac®: Canine Flu Bivalent
Canine influenza virus
U.S. Patent No. 7,959,929
U.S. Patent No. 9,345,758
U.S. Patent No. 8,246,962
Nobivac®: Canine Flu H3N8
Canine influenza virus
U.S. Patent No. 7,959,929
U.S. Patent No. 9,345,758
Nobivac®: Lyme
Borrelia Burgdorferi Bacterin
U.S. Patent No. 8,137,678
U.S. Patent No. 8,414,901
Nuflor Gold™
Florfenicol
U.S. Patent No. 8,034,845
Orbax® Oral Suspension
Orbifloxacin
U.S. Patent No. 6,514,492
Posatex™ Otic Suspension
Orbifloxacin, Mometasone Furoate monohydrate and Posaconazole, Suspension
U.S. Patent No. 6,127,353
U.S. Patent No. 5,661,151
U.S. Patent No. 8,084,445
U.S. Patent No. 8,609,645
Prestige® V+ WNV with Havlogen®
ENCEPHALOMYELITIS-RHINOPNEUMONITIS-INFLUENZA-WEST NILE VIRUS VACCINE, Eastern and Western Killed Virus, Killed Flavivirus Chimera
U.S. Patent No. 8,048,459
U.S. Patent No. 8,133,712
Resflor Gold®
Florfenicol and Flunixin Meglumine
U.S. Patent No. 6,787,568
U.S. Patent No. 6,790,867
U.S. Patent No. 8,044,102
Revolor-XS
Trenbolone acetate and Estradiol
U.S. Patent No. RE39, 592
Vision® 8 Somnus with SPUR®
Clostridium Chauvoei-Septicum-Haemolyticum-Novyi-Sordellii-Perfringens Types C&D-Haemophilus Somnus Bacterin-Toxoid with SPUR

U.S. Patent No. 6,743,430
Zilmax®
Zilpaterol hydrochloride
U.S. Patent No. 8,580,772
Zuprevo™
Tildipirosin
U.S. Patent No. 6,514,946
U.S. Patent No. 8,227,429

Revised Date: 1/31/17



A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | X | Y | Z



ASMANEX HFA®
(mometasone furoate aerosol, inhalation)
U.S. Patent No. 6,068,832
ASMANEX® TWISTHALER®
(mometasone furoate inhalation powder)
U.S. Patent No. 6.240,918
U.S. Patent No. 6,503,537
U.S. Patent No. 8,173,172
BELSOMRA®
(suvorexant)
Tablets
U.S. Patent No. 7,951,797
BRIDION™
(sugammadex sodium injection)
For intravenous use
U.S. Patent No. RE44,733
CANCIDAS®
(caspofungin acetate)
U.S. Patent No. 5,952,300
CLARINEX®
Tablets
(desloratadine) for oral use
U.S. Patent No. 6,100,274
CLARINEX®
RediTabs
(desloratadine) for oral use
U.S. Patent No. 6,100,274
U.S. Patent No. 7,618,649
CLARINEX®
Oral Solution
(desloratadine) for oral use
U.S. Patent No. 6,514,520
CLARINEX-D® 12 HOUR
Extended Release Tablets
(desloratadine/ pseudoephedrine sulfate) for oral use

U.S. Patent No. 6,100,274
U.S. Patent No. 6,709,676
U.S. Patent No. 7,618,649
CLARINEX-D® 24 HOUR
Extended Release Tablets
(desloratadine/ pseudoephedrine sulfate) for oral use
U.S. Patent No. 6,100,274
U.S. Patent No. 7,618,649
CRIXIVAN®
(indinavir sulfate)
Capsules
U.S. Patent No. 6,645,961
DIFICID®
(fidaxomicin)
Tablets for oral use
U.S. Patent No. 8,586,551
U.S. Patent No. 7,863,249
U.S. Patent No. 7,378,508
DULERA®
(mometasone furoate and formoterol fumarate dihydrate)
Inhalation Aerosol
U.S. Patent No. 6,068,832
U.S. Patent No. 7,067,502
U.S. Patent No. 7,566,705
EMEND IV®
(fosaprepitant dimeglumine)
for Injection, for intravenous use
U.S. Patent No. 5,691,336
EMEND®
(aprepitant)
Capsules 125/80 mg
U.S. Patent No. 6,096,742
U.S. Patent No. 8,258,132
EMEND®
(aprepitant)
Capsules 40mg
U.S. Patent No. 6,096,742
U.S. Patent No. 8,258,132
EMEND®
(aprepitant)
for oral suspension (125 mg)
U.S. Patent No. 6,096,742
U.S. Patent No. 8,258,132
Follistim® AQ
(follitropin beta injection)
for subcutaneous or intramuscular use
U.S. Patent No. 5,929,028
Follistim® AQ Cartridge
(follitropin beta injection)
for subcutaneous use
U.S. Patent No. 5,929,028
U.S. Patent No. 7,446,090
U.S. Patent No. 7,563,763
Ganirelix Acetate Injection
ganirelix acetate
for subcutaneous use
U.S. Patent No. 6,653,286
INTRON® A
Interferon alfa-2b, recombinant For Injection
Powder for Injection
U.S. Patent No. 6,610,830
INTRON® A
Interferon alfa-2b, recombinant For Injection
Solution Vials for Injection
U.S. Patent No. 6,610,830
INTRON® A
Interferon alfa-2b, recombinant For Injection
Solution in Multidose Pens for Injection
U.S. Patent No. 6,610,830
INVANZ®
(ertapenem for injection)
For intravenous (IV) or intramuscular (IM) use
U.S. Patent No. 5,952,323
ISENTRESS®
(raltegravir)
Film-coated Tablets for oral use
U.S. Patent No. 7,169,780
U.S. Patent No. 7,754,731
ISENTRESS®
(raltegravir)
Chewable Tablets for oral use
U.S. Patent No. 7,169,780
U.S. Patent No. 7,754,731
JANUMET®
(sitagliptin/metformin HCl)
Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
U.S. Patent No. 7,125,873
JANUMET® XR
(sitagliptin and metformin HCl extended-release)
Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
U.S. Patent No. 7,125,873
JANUVIA®
(sitagliptin)
Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
JUVISYNC™
(sitagliptin and simvastatin)
Tablets
U.S. Patent No. 6,699,871
U.S. Patent No. 7,326,708
U.S. Patent No. 7,125,873
U.S. Patent No. 8,168,637
KEYTRUDA®
(pembrolizumab)
For Injection
50 mg
U.S. Patent No. 8,354,509
U.S. Patent No. 8,900,587
NASONEX®
(mometasone furoate monohydrate)
Nasal Spray, 50 mcg†
†calculated on the anhydrous basis
U.S. Patent No. 6,127,353
NEXPLANON®
(etonogestrel)
Implant
U.S. Patent No. 8,722,037
NOXAFIL®
(Posaconazole)
Oral Suspension 40 mg/mL Injection 18 mg/mL Delayed-Release Tablet 100 mg
U.S. Patent No. 5,661,151
NuvaRing®
(etonogestrel/ethinyl estradiol)
Vaginal Ring
U.S. Patent No. 5,989,581
PegIntron®
(Peginterferon alfa-2b) Injection, Powder for Solution for Subcutaneous Use
Single-Use Vial (with 1.25 mL diluent)
U.S. Patent No. 6,180,096
U.S. Patent No. 6,610,830
PegIntron®
(Peginterferon alfa-2b) Injection, Powder for Solution for Subcutaneous Use
REDIPEN®
U.S. Patent No. 6,180,096
U.S. Patent No. 6,610,830
SIVEXTRO®
(tedizolid phosphate)
Powder for Infusion and Oral tablets
U.S. Patent No. 7,816,379
U.S. Patent No. 8,420,676
SYLATRON™
(peginterferon alfa-2b) for injection, for subcutaneous use
Lyophilized powder in single-use vial
U.S. Patent No. 6,180,096
U.S. Patent No. 6,610,830
TEMODAR®
(temozolomide)
for Injection
U.S. Patent No. 6,987,108
U.S. Patent No. 7,786,118
U.S. Patent No. 8,623,868
VYTORIN®
(ezetimibe/simvastatin)
Tablets
U.S. Patent No. RE42,461
ZEPATIER™
(elbasvir/grazoprevir)
Tablets for oral use
U.S. Patent No. 8,871,759
U.S. Patent No. 7,973,040
ZERBAXA™
(ceftolozane sulfate/tazobactam sodium)
Powder for Infusion
U.S. Patent No. 7,129,232
ZETIA®
(ezetimibe)
Tablets
U.S. Patent No. 7,030,106
ZOLINZA®
(vorinostat)
Capsules
U.S. Patent No. 7,456,219
U.S. Patent No. 7,652,069
U.S. Patent No. 7,851,509
U.S. Patent No. 8,093,295

Revised Date: 1/31/17



A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | X | Y | Z



Comvax®
[HAEMOPHILUS b CONJUGATE (MENINGOCOCCAL PROTEIN CONJUGATE) and HEPATITIS B (RECOMBINANT) VACCINE]
U.S. Patent No. 6,544,757
Recombivax®
HEPATITIS B VACCINE (RECOMBINANT)
U.S. Patent No. 6,544,757

Revised Date: 1/31/17